Details for Patent: 9,463,161
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,463,161 protect, and when does it expire?
Patent 9,463,161 protects BEVESPI AEROSPHERE and BREZTRI AEROSPHERE and is included in two NDAs.
This patent has one hundred and eighty-one patent family members in thirty-one countries.
Summary for Patent: 9,463,161
| Title: | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
| Abstract: | Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting .beta..sub.2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium. |
| Inventor(s): | Vehring; Reinhard (Edmonton, CA), Hartman; Michael Steven (Millbrae, CA), Smith; Adrian Edward (Emerald Hills, CA), Joshi; Vidya B. (Redwood City, CA), Dwivedi; Sarvajna Kumar (Redwood City, CA) |
| Assignee: | Pearl Therapeutics, Inc. (Redwood City, CA) |
| Application Number: | 12/790,448 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 9,463,161
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | BEVESPI AEROSPHERE | formoterol fumarate; glycopyrrolate | AEROSOL, METERED;INHALATION | 208294-001 | Apr 25, 2016 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | See Plans and Pricing | |||
| Astrazeneca Ab | BREZTRI AEROSPHERE | budesonide; formoterol fumarate; glycopyrrolate | AEROSOL, METERED;INHALATION | 212122-001 | Jul 23, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,463,161
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 076621 | See Plans and Pricing | |||
| Argentina | 076806 | See Plans and Pricing | |||
| Argentina | 076807 | See Plans and Pricing | |||
| Argentina | 121758 | See Plans and Pricing | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
